A Study of V118E in Healthy Participants (V118E-003)

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC
    • Enrollment closed, study ongoing
    • Site details revised at 4 of 4 sites
    • Eligibility criteria expanded, about 2 words
  2. Primary and study completion moved earlier from Nov 12, 2027 to Jul 6, 2027v10
  3. Site details revised at 2 of 4 sitesv9
  4. Primary and study completion dates: May 10, 2027 to Nov 12, 2027v8
  5. Primary and study completion dates: Apr 8, 2027 to May 10, 2027v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 3 to 4v6
  2. Study sites: 2 to 3v5
  3. Study sites: 1 to 2v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Primary and study completion dates: Feb 9, 2027 to Apr 8, 2027
    • Start date changed from estimate of Oct 10, 2025 to Oct 8, 2025
    v3
  5. Start date: Oct 6, 2025 to Oct 10, 2025v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
412 trials monitored
See 26 trials at risk
Researchers are looking for new vaccines to prevent illnesses caused by a type of bacteria called Streptococcus pneumoniae. There are many different types of Streptococcus pneumoniae bacteria, called serotypes. Vaccines contain small parts of certain serotypes. These parts will not cause an infection but help the body create antibodies (proteins) to fight the bacteria. PREVNAR 20™ is a vaccine given to help to prevent disease from Streptococcus pneumoniae bacteria. Researchers designed a new vaccine, V118E, to help prevent disease from Streptococcus pneumoniae bacteria. The goal of this study is to learn how safe V118 formulation E is in Healthy Adults and how well people tolerate it.
Trial Details
NCT Number NCT07168915
Lead Sponsor Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Healthy
Enrollment 126 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov